title: Effects of dopamine and dopamine-active compounds on oxytocin and vasopressin production in rat neurohypophyseal tissue cultures.
abstract: The effects of dopamine (DA) or DA-active drugs on the synthesis of neurohypophyseal (NH) hormones were studied in 13-14 day cultures of isolated NH tissue from rats. The following DA-active compounds were used (10(-6) M in each medium): DA, apomorphine (APM), Pro-Lys-Gly (PLG), butaclamol (B), haloperidol (HP), chlorpromazine (CPZ) and sulpiride (SP). The oxytocin (OT) and vasopressin (VP) contents of the condensed media were determined by RIA after a 1 or 2 h incubation. Significantly increased contents of OT and VP were detected in the tissue culture media following DA, APM or PLG administration. This elevation of NH hormone production could be blocked by previous administration of B or the DA receptor antagonists HP, CPZ or SP. The application of B after DA agonists proved ineffective. The results indicate that NH hormone production can be directly influenced by the DA-ergic system. The DA-ergic control of NH hormone secretion in rats can occur independently of the hypothalamus, at the level of the posterior pituitary.
authors.affiliation: Department of Biology, University of Sciences, Faculty of Juhász Gyula Teachers' College, Szeged, Hungary. berko@bio.u-szeged.hu
authors.forename: M
authors.initials: M
authors.lastname: Gálfi
authors.forename: T
authors.initials: T
authors.lastname: Janáky
authors.forename: R
authors.initials: R
authors.lastname: Tóth
authors.forename: G
authors.initials: G
authors.lastname: Prohászka
authors.forename: A
authors.initials: A
authors.lastname: Juhász
authors.forename: C
authors.initials: C
authors.lastname: Varga
authors.forename: F A
authors.initials: FA
authors.lastname: László
mesh_terms: D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D002069:Butaclamol / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D046508:Culture Techniques; D004298:Dopamine / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology*; D004357:Drug Synergism; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D009457:Neuroglia / Q000187:drug effects / Q000378:metabolism; D010121:Oxytocin / Q000187:drug effects / Q000378:metabolism*; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013469:Sulpiride / Q000494:pharmacology; D014667:Vasopressins / Q000187:drug effects / Q000378:metabolism*
chemical_list: D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D014667:Vasopressins; D010121:Oxytocin; D013469:Sulpiride; D002069:Butaclamol; D006220:Haloperidol; D001058:Apomorphine; D002746:Chlorpromazine; D004298:Dopamine